A 4-amino-acid synthetic peptide (Ala-Glu-Asp-Gly) based on the natural peptide epithalamin, which is produced by the pineal gland. Studied for telomerase activation, telomere elongation, and potential anti-aging effects. Primarily researched in Russia.
Epithalon (also spelled Epitalon) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly. It is based on epithalamin, a peptide extract from the pineal gland first studied by Professor Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology in Russia.
Epithalon is primarily studied for its reported ability to activate telomerase — the enzyme that lengthens telomeres (the protective caps on chromosome ends). Telomere shortening is one of the hallmarks of aging, and telomerase activation is a major area of anti-aging research. However, the evidence base is primarily from Russian research groups, and independent replication is limited.
The proposed mechanism is that Epithalon stimulates expression of the hTERT gene, which encodes the reverse transcriptase catalytic subunit of telomerase. In most somatic cells, hTERT is epigenetically silenced after embryonic development, leading to progressive telomere shortening with each cell division. Reactivating hTERT — even partially — could restore telomere maintenance and extend replicative capacity.
| Pathway | Effect | Significance |
|---|---|---|
| Telomerase activation | Increases hTERT expression in somatic cells | Reported to restore telomere length in human fibroblasts |
| Melatonin regulation | Stimulates pineal gland melatonin production | May improve sleep quality and circadian rhythm |
| Antioxidant effects | Increases SOD and other antioxidant enzyme activity | Reduces oxidative stress — a driver of telomere shortening |
| Cell cycle regulation | Normalizes cell cycle in senescent cells | May delay entry into senescence |
| Study | Design | Findings | Level |
|---|---|---|---|
| Telomerase activation | In vitro, human fibroblasts | Epithalon treatment increased telomerase activity and telomere length in cultured human cells (Khavinson lab) | Preclinical |
| Lifespan studies | Animal (mice, rats, Drosophila) | Some studies report increased lifespan (10-15% in mice), improved immune function, and delayed tumor onset | Preclinical |
| Human clinical (Russian) | Clinical study, elderly patients | Reported improvements in immune markers, melatonin levels, and mortality over 6-year follow-up (Khavinson et al.) | Level II-III (limited) |
| Retinal health | Animal studies | Protected retinal cells from degeneration in aging rats | Preclinical |
No reported adverse effects: Preclinical and limited clinical studies report no significant toxicity.
Telomerase and cancer concern: Telomerase activation is a hallmark of cancer cells. Long-term effects of exogenous telomerase activation on cancer risk are unknown.
Limited independent validation: Most research originates from one group (Khavinson lab). Independent replication is needed.
Regulatory uncertainty: Not manufactured under pharmaceutical-grade conditions for consumer use.
| Jurisdiction | Status |
|---|---|
| FDA | Not approved. Not reviewed. |
| Russia | Studied extensively at government research institutes. Not formally approved as a drug. |
| WADA | Not specifically listed |